Horizon scanning: US FDA accepts for review peginesatide for the treatment of anaemia associated with chronic kidney disease

Homepage

Search the NeLM

Medicines A-Z

Find key information about medicines by name (prototype)

Browse by Categories:

Browse by NeLM area:

NeLM news service

Horizon scanning: US FDA accepts for review peginesatide for the treatment of anaemia associated with chronic kidney disease

Source: BioSpace.com

Date published: 25/10/2011 16:59

Summary

by: Hina Radia

According to a report by BioSpace.com, the US Food and Drug Administration has accepted for review, a new drug application for peginesatide for the treatment of anaemia associated with chronic kidney disease (CKD).

About this library entry

Category: Anaemias | Food &Drug Administration (FDA) | New drugs | Renal medicine

NeLM area: News

Link

Preview your comment

Add new comment

Comment text:

Comments

There are no comments yet. You could be the first! You must be Logged In to comment.

Printer Friendly Version

Related evidence

Anaemias

06/09/2011

AWMSG issues Final Appraisal Recommendation on ferric carboxymaltose (Ferinject®)

09/05/2011

SMC accepts restricted use of iron isomaltoside (Monofer) within NHS Scotland.

05/04/2011

Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia: summary of trials of cancer, HIV/AIDS, and chronic kidney disease

Renal medicine

14/02/2012

SMC unable to recommend eculizumab (Soliris™) for atypical haemolytic uremic syndrome due to non-submission

05/02/2012

Parenteral versus oral iron therapy for adults and children with chronic kidney disease

08/08/2011

SMC accepts restricted use of alteplase (Actilyse Cathflo®) for thrombolytic treatment of occluded central venous access devices